APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate API

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Imatinib Mesylate API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025196 pages

Choose your research edition.

Industry ResearchImatinib Mesylate API Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate API Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate API Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate API Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate API market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Imatinib Mesylate API include Zhejiang Jiuzhou Pharmaceutical Co Ltd, Sun Pharma, Shanghai Yuanye Bio-Technology, Shandong Anxin Pharmaceutical Co Ltd, Mylan, Zydus Lifesciences Ltd, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd and Shilpa Pharma Lifesciences Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Imatinib Mesylate API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Imatinib Mesylate API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Imatinib Mesylate API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Imatinib Mesylate API market size, projected growth trends, production technologies, key applications, and end-use industries.

Imatinib Mesylate API Segment by Company

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Sun Pharma

Shanghai Yuanye Bio-Technology

Shandong Anxin Pharmaceutical Co Ltd

Mylan

Zydus Lifesciences Ltd

Zydus Lifesciences

Sun Pharmaceutical Industries Ltd

Shilpa Pharma Lifesciences Ltd

Natco Pharma Ltd

Msn Laboratories Private Ltd

Laurus Labs Ltd

Intas Pharmaceuticals Ltd

Hetero Labs Ltd

Dr. Reddy’s

Cipla Ltd

Aurobindo Pharma Ltd

Acebright India Pharma Private Ltd

Imatinib Mesylate API Segment by Type

Purity ≥ 98%

Purity < 98%

Imatinib Mesylate API Segment by Application

Chronic Myeloid Leukemia (CML)

Gastrointestinal Stromal Tumor (GIST)

Others

Imatinib Mesylate API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Imatinib Mesylate API market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Imatinib Mesylate API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Imatinib Mesylate API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Imatinib Mesylate API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Imatinib Mesylate API Industry Trends Table 2. Imatinib Mesylate API Industry Drivers Table 3. Imatinib Mesylate API Industry Opportunities and Challenges Table 4. Imatinib Mesylate API Industry Restraints Table 5. Global Imatinib Mesylate API Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Imatinib Mesylate API Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Imatinib Mesylate API Sales by Manufacturers (kg) & (2021-2026) Table 8. Global Imatinib Mesylate API Sales Market Share by Manufacturers Table 9. Global Imatinib Mesylate API Average Sales Price (USD/g) of Manufacturers (2021-2026) Table 10. Global Imatinib Mesylate API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Imatinib Mesylate API Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Imatinib Mesylate API Manufacturers, Product Type & Application Table 13. Global Imatinib Mesylate API Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Imatinib Mesylate API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Purity ≥ 98% Table 17. Major Manufacturers of Purity < 98% Table 18. Global Imatinib Mesylate API Sales by Type 2021 VS 2025 VS 2032 (kg) Table 19. Global Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 20. Global Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 21. Global Imatinib Mesylate API Sales Market Share by Type (2021-2026) Table 22. Global Imatinib Mesylate API Sales Market Share by Type (2027-2032) Table 23. Global Imatinib Mesylate API Revenue by Type 2021 VS 2025 VS 2032 (kg) Table 24. Global Imatinib Mesylate API Revenue by Type (2021-2026) & (kg) Table 25. Global Imatinib Mesylate API Revenue by Type (2027-2032) & (kg) Table 26. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2026) Table 27. Global Imatinib Mesylate API Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Chronic Myeloid Leukemia (CML) Table 29. Major Manufacturers of Gastrointestinal Stromal Tumor (GIST) Table 30. Major Manufacturers of Others Table 31. Global Imatinib Mesylate API Sales by Application 2021 VS 2025 VS 2032 (kg) Table 32. Global Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 33. Global Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 34. Global Imatinib Mesylate API Sales Market Share by Application (2021-2026) Table 35. Global Imatinib Mesylate API Sales Market Share by Application (2027-2032) Table 36. Global Imatinib Mesylate API Revenue by Application 2021 VS 2025 VS 2032 (kg) Table 37. Global Imatinib Mesylate API Revenue by Application (2021-2026) & (kg) Table 38. Global Imatinib Mesylate API Revenue by Application (2027-2032) & (kg) Table 39. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2026) Table 40. Global Imatinib Mesylate API Revenue Market Share by Application (2027-2032) Table 41. Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 42. Global Imatinib Mesylate API Sales by Region (2021-2026) & (kg) Table 43. Global Imatinib Mesylate API Sales Market Share by Region (2021-2026) Table 44. Global Imatinib Mesylate API Sales Forecasted by Region (2027-2032) & (kg) Table 45. Global Imatinib Mesylate API Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 47. North America Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 48. North America Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 49. Europe Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 50. Europe Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 51. Europe Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 52. Asia Pacific Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 53. Asia Pacific Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 54. Asia Pacific Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 55. South America, Middle East and Africa Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 56. South America, Middle East and Africa Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 57. South America, Middle East and Africa Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 58. Global Imatinib Mesylate API Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Imatinib Mesylate API Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Imatinib Mesylate API Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Imatinib Mesylate API Revenue Market Share by Region (2021-2026) Table 62. Global Imatinib Mesylate API Revenue Market Share by Region (2027-2032) Table 63. Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information Table 64. Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview Table 65. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 67. Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Development Table 68. Sun Pharma Company Information Table 69. Sun Pharma Business Overview Table 70. Sun Pharma Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sun Pharma Imatinib Mesylate API Product Portfolio Table 72. Sun Pharma Recent Development Table 73. Shanghai Yuanye Bio-Technology Company Information Table 74. Shanghai Yuanye Bio-Technology Business Overview Table 75. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio Table 77. Shanghai Yuanye Bio-Technology Recent Development Table 78. Shandong Anxin Pharmaceutical Co Ltd Company Information Table 79. Shandong Anxin Pharmaceutical Co Ltd Business Overview Table 80. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 82. Shandong Anxin Pharmaceutical Co Ltd Recent Development Table 83. Mylan Company Information Table 84. Mylan Business Overview Table 85. Mylan Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Mylan Imatinib Mesylate API Product Portfolio Table 87. Mylan Recent Development Table 88. Zydus Lifesciences Ltd Company Information Table 89. Zydus Lifesciences Ltd Business Overview Table 90. Zydus Lifesciences Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 92. Zydus Lifesciences Ltd Recent Development Table 93. Zydus Lifesciences Company Information Table 94. Zydus Lifesciences Business Overview Table 95. Zydus Lifesciences Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Zydus Lifesciences Imatinib Mesylate API Product Portfolio Table 97. Zydus Lifesciences Recent Development Table 98. Sun Pharmaceutical Industries Ltd Company Information Table 99. Sun Pharmaceutical Industries Ltd Business Overview Table 100. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio Table 102. Sun Pharmaceutical Industries Ltd Recent Development Table 103. Shilpa Pharma Lifesciences Ltd Company Information Table 104. Shilpa Pharma Lifesciences Ltd Business Overview Table 105. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 107. Shilpa Pharma Lifesciences Ltd Recent Development Table 108. Natco Pharma Ltd Company Information Table 109. Natco Pharma Ltd Business Overview Table 110. Natco Pharma Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Natco Pharma Ltd Imatinib Mesylate API Product Portfolio Table 112. Natco Pharma Ltd Recent Development Table 113. Msn Laboratories Private Ltd Company Information Table 114. Msn Laboratories Private Ltd Business Overview Table 115. Msn Laboratories Private Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio Table 117. Msn Laboratories Private Ltd Recent Development Table 118. Laurus Labs Ltd Company Information Table 119. Laurus Labs Ltd Business Overview Table 120. Laurus Labs Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Laurus Labs Ltd Imatinib Mesylate API Product Portfolio Table 122. Laurus Labs Ltd Recent Development Table 123. Intas Pharmaceuticals Ltd Company Information Table 124. Intas Pharmaceuticals Ltd Business Overview Table 125. Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio Table 127. Intas Pharmaceuticals Ltd Recent Development Table 128. Hetero Labs Ltd Company Information Table 129. Hetero Labs Ltd Business Overview Table 130. Hetero Labs Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Hetero Labs Ltd Imatinib Mesylate API Product Portfolio Table 132. Hetero Labs Ltd Recent Development Table 133. Dr. Reddy’s Company Information Table 134. Dr. Reddy’s Business Overview Table 135. Dr. Reddy’s Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Dr. Reddy’s Imatinib Mesylate API Product Portfolio Table 137. Dr. Reddy’s Recent Development Table 138. Cipla Ltd Company Information Table 139. Cipla Ltd Business Overview Table 140. Cipla Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Cipla Ltd Imatinib Mesylate API Product Portfolio Table 142. Cipla Ltd Recent Development Table 143. Aurobindo Pharma Ltd Company Information Table 144. Aurobindo Pharma Ltd Business Overview Table 145. Aurobindo Pharma Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio Table 147. Aurobindo Pharma Ltd Recent Development Table 148. Acebright India Pharma Private Ltd Company Information Table 149. Acebright India Pharma Private Ltd Business Overview Table 150. Acebright India Pharma Private Ltd Imatinib Mesylate API Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio Table 152. Acebright India Pharma Private Ltd Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Imatinib Mesylate API Distributors List Table 156. Imatinib Mesylate API Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Imatinib Mesylate API Product Image Figure 2. Global Imatinib Mesylate API Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Mesylate API Market Size (2021-2032) & (US$ Million) Figure 4. Global Imatinib Mesylate API Sales (2021-2032) & (kg) Figure 5. Global Imatinib Mesylate API Average Price (USD/g) & (2021-2032) Figure 6. Global Top 5 and 10 Imatinib Mesylate API Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Purity ≥ 98% Image Figure 9. Purity < 98% Image Figure 10. Global Imatinib Mesylate API Sales by Type (2021 VS 2025 VS 2032) & (kg) Figure 11. Global Imatinib Mesylate API Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Imatinib Mesylate API Sales Market Share by Type (2021-2032) Figure 13. Global Imatinib Mesylate API Revenue by Type (2021 VS 2025 VS 2032) & (kg) Figure 14. Global Imatinib Mesylate API Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032) Figure 16. Chronic Myeloid Leukemia (CML) Image Figure 17. Gastrointestinal Stromal Tumor (GIST) Image Figure 18. Others Image Figure 19. Global Imatinib Mesylate API Sales by Application (2021 VS 2025 VS 2032) & (kg) Figure 20. Global Imatinib Mesylate API Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Imatinib Mesylate API Sales Market Share by Application (2021-2032) Figure 22. Global Imatinib Mesylate API Revenue by Application (2021 VS 2025 VS 2032) & (kg) Figure 23. Global Imatinib Mesylate API Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032) Figure 25. North America Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 26. North America Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 27. U.S. Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 28. Canada Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 29. Mexico Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 30. Europe Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 31. Europe Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 32. Germany Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 33. France Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 34. U.K. Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 35. Italy Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 36. Netherlands Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 37. Asia Pacific Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 38. Asia Pacific Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 39. China Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 40. Japan Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 41. South Korea Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 42. Southeast Asia Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 43. India Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 44. Australia Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 45. South America, Middle East and Africa Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 46. South America, Middle East and Africa Imatinib Mesylate API Sales Market Share by Country (2021-2032) Figure 47. Brazil Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 48. South Africa Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 49. Saudi Arabia Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 50. Turkey Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 51. Argentina Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 52. UAE Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 53. Egypt Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 54. Chile Imatinib Mesylate API Sales and Growth Rate (2021-2032) & (kg) Figure 55. Global Imatinib Mesylate API Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Imatinib Mesylate API Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Figure 58. North America Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Figure 60. Europe Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Imatinib Mesylate API Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Imatinib Mesylate API Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Purity ≥ 98%
  • Purity < 98%
Applications
  • Chronic Myeloid Leukemia (CML)
  • Gastrointestinal Stromal Tumor (GIST)
  • Others
Companies covered
  • Zhejiang Jiuzhou Pharmaceutical Co Ltd
  • Sun Pharma
  • Shanghai Yuanye Bio-Technology
  • Shandong Anxin Pharmaceutical Co Ltd
  • Mylan
  • Zydus Lifesciences Ltd
  • Zydus Lifesciences
  • Sun Pharmaceutical Industries Ltd
  • Shilpa Pharma Lifesciences Ltd
  • Natco Pharma Ltd
  • Msn Laboratories Private Ltd
  • Laurus Labs Ltd
  • Intas Pharmaceuticals Ltd
  • Hetero Labs Ltd
  • Dr. Reddy’s
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Acebright India Pharma Private Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Imatinib Mesylate API Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Imatinib Mesylate API Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Imatinib Mesylate API Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Imatinib Mesylate API Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Imatinib Mesylate API Market Dynamics
  1. 2.1 Imatinib Mesylate API Industry Trends
  2. 2.2 Imatinib Mesylate API Industry Drivers
  3. 2.3 Imatinib Mesylate API Industry Opportunities and Challenges
  4. 2.4 Imatinib Mesylate API Industry Restraints
3 Imatinib Mesylate API Market by Manufacturers
  1. 3.1 Global Imatinib Mesylate API Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Imatinib Mesylate API Sales by Manufacturers (2021-2026)
  3. 3.3 Global Imatinib Mesylate API Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Imatinib Mesylate API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Imatinib Mesylate API Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Imatinib Mesylate API Manufacturers, Product Type & Application
  7. 3.7 Global Imatinib Mesylate API Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Imatinib Mesylate API Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Imatinib Mesylate API Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Imatinib Mesylate API Tier 1, Tier 2, and Tier 3
4 Imatinib Mesylate API Market by Type
  1. 4.1 Imatinib Mesylate API Type Introduction
  2. 4.1.1 Purity ≥ 98%
  3. 4.1.2 Purity < 98%
  4. 4.2 Global Imatinib Mesylate API Sales by Type
  5. 4.2.1 Global Imatinib Mesylate API Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Imatinib Mesylate API Sales by Type (2021-2032)
  7. 4.2.3 Global Imatinib Mesylate API Sales Market Share by Type (2021-2032)
  8. 4.3 Global Imatinib Mesylate API Revenue by Type
  9. 4.3.1 Global Imatinib Mesylate API Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Imatinib Mesylate API Revenue by Type (2021-2032)
  11. 4.3.3 Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032)
5 Imatinib Mesylate API Market by Application
  1. 5.1 Imatinib Mesylate API Application Introduction
  2. 5.1.1 Chronic Myeloid Leukemia (CML)
  3. 5.1.2 Gastrointestinal Stromal Tumor (GIST)
  4. 5.1.3 Others
  5. 5.2 Global Imatinib Mesylate API Sales by Application
  6. 5.2.1 Global Imatinib Mesylate API Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Imatinib Mesylate API Sales by Application (2021-2032)
  8. 5.2.3 Global Imatinib Mesylate API Sales Market Share by Application (2021-2032)
  9. 5.3 Global Imatinib Mesylate API Revenue by Application
  10. 5.3.1 Global Imatinib Mesylate API Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Imatinib Mesylate API Revenue by Application (2021-2032)
  12. 5.3.3 Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032)
6 Global Imatinib Mesylate API Sales by Region
  1. 6.1 Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Imatinib Mesylate API Sales by Region (2021-2032)
  3. 6.2.1 Global Imatinib Mesylate API Sales by Region (2021-2026)
  4. 6.2.2 Global Imatinib Mesylate API Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Imatinib Mesylate API Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Imatinib Mesylate API Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Imatinib Mesylate API Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Imatinib Mesylate API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Imatinib Mesylate API Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Imatinib Mesylate API Revenue by Region
  1. 7.1 Global Imatinib Mesylate API Revenue by Region
  2. 7.1.1 Global Imatinib Mesylate API Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Imatinib Mesylate API Revenue by Region (2021-2026)
  4. 7.1.3 Global Imatinib Mesylate API Revenue by Region (2027-2032)
  5. 7.1.4 Global Imatinib Mesylate API Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Imatinib Mesylate API Revenue (2021-2032)
  8. 7.2.2 North America Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Imatinib Mesylate API Revenue (2021-2032)
  11. 7.3.2 Europe Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Imatinib Mesylate API Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Imatinib Mesylate API Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Imatinib Mesylate API Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd
  2. 8.1.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  6. 8.1.5 Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments
  7. 8.2 Sun Pharma
  8. 8.2.1 Sun Pharma Company Information
  9. 8.2.2 Sun Pharma Business Overview
  10. 8.2.3 Sun Pharma Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharma Imatinib Mesylate API Product Portfolio
  12. 8.2.5 Sun Pharma Recent Developments
  13. 8.3 Shanghai Yuanye Bio-Technology
  14. 8.3.1 Shanghai Yuanye Bio-Technology Company Information
  15. 8.3.2 Shanghai Yuanye Bio-Technology Business Overview
  16. 8.3.3 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio
  18. 8.3.5 Shanghai Yuanye Bio-Technology Recent Developments
  19. 8.4 Shandong Anxin Pharmaceutical Co Ltd
  20. 8.4.1 Shandong Anxin Pharmaceutical Co Ltd Company Information
  21. 8.4.2 Shandong Anxin Pharmaceutical Co Ltd Business Overview
  22. 8.4.3 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  24. 8.4.5 Shandong Anxin Pharmaceutical Co Ltd Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Imatinib Mesylate API Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Zydus Lifesciences Ltd
  32. 8.6.1 Zydus Lifesciences Ltd Company Information
  33. 8.6.2 Zydus Lifesciences Ltd Business Overview
  34. 8.6.3 Zydus Lifesciences Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  36. 8.6.5 Zydus Lifesciences Ltd Recent Developments
  37. 8.7 Zydus Lifesciences
  38. 8.7.1 Zydus Lifesciences Company Information
  39. 8.7.2 Zydus Lifesciences Business Overview
  40. 8.7.3 Zydus Lifesciences Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Lifesciences Imatinib Mesylate API Product Portfolio
  42. 8.7.5 Zydus Lifesciences Recent Developments
  43. 8.8 Sun Pharmaceutical Industries Ltd
  44. 8.8.1 Sun Pharmaceutical Industries Ltd Company Information
  45. 8.8.2 Sun Pharmaceutical Industries Ltd Business Overview
  46. 8.8.3 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Industries Ltd Recent Developments
  49. 8.9 Shilpa Pharma Lifesciences Ltd
  50. 8.9.1 Shilpa Pharma Lifesciences Ltd Company Information
  51. 8.9.2 Shilpa Pharma Lifesciences Ltd Business Overview
  52. 8.9.3 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  54. 8.9.5 Shilpa Pharma Lifesciences Ltd Recent Developments
  55. 8.10 Natco Pharma Ltd
  56. 8.10.1 Natco Pharma Ltd Company Information
  57. 8.10.2 Natco Pharma Ltd Business Overview
  58. 8.10.3 Natco Pharma Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Natco Pharma Ltd Imatinib Mesylate API Product Portfolio
  60. 8.10.5 Natco Pharma Ltd Recent Developments
  61. 8.11 Msn Laboratories Private Ltd
  62. 8.11.1 Msn Laboratories Private Ltd Company Information
  63. 8.11.2 Msn Laboratories Private Ltd Business Overview
  64. 8.11.3 Msn Laboratories Private Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio
  66. 8.11.5 Msn Laboratories Private Ltd Recent Developments
  67. 8.12 Laurus Labs Ltd
  68. 8.12.1 Laurus Labs Ltd Company Information
  69. 8.12.2 Laurus Labs Ltd Business Overview
  70. 8.12.3 Laurus Labs Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Laurus Labs Ltd Imatinib Mesylate API Product Portfolio
  72. 8.12.5 Laurus Labs Ltd Recent Developments
  73. 8.13 Intas Pharmaceuticals Ltd
  74. 8.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 8.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 8.13.3 Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio
  78. 8.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 8.14 Hetero Labs Ltd
  80. 8.14.1 Hetero Labs Ltd Company Information
  81. 8.14.2 Hetero Labs Ltd Business Overview
  82. 8.14.3 Hetero Labs Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hetero Labs Ltd Imatinib Mesylate API Product Portfolio
  84. 8.14.5 Hetero Labs Ltd Recent Developments
  85. 8.15 Dr. Reddy’s
  86. 8.15.1 Dr. Reddy’s Company Information
  87. 8.15.2 Dr. Reddy’s Business Overview
  88. 8.15.3 Dr. Reddy’s Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dr. Reddy’s Imatinib Mesylate API Product Portfolio
  90. 8.15.5 Dr. Reddy’s Recent Developments
  91. 8.16 Cipla Ltd
  92. 8.16.1 Cipla Ltd Company Information
  93. 8.16.2 Cipla Ltd Business Overview
  94. 8.16.3 Cipla Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cipla Ltd Imatinib Mesylate API Product Portfolio
  96. 8.16.5 Cipla Ltd Recent Developments
  97. 8.17 Aurobindo Pharma Ltd
  98. 8.17.1 Aurobindo Pharma Ltd Company Information
  99. 8.17.2 Aurobindo Pharma Ltd Business Overview
  100. 8.17.3 Aurobindo Pharma Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio
  102. 8.17.5 Aurobindo Pharma Ltd Recent Developments
  103. 8.18 Acebright India Pharma Private Ltd
  104. 8.18.1 Acebright India Pharma Private Ltd Company Information
  105. 8.18.2 Acebright India Pharma Private Ltd Business Overview
  106. 8.18.3 Acebright India Pharma Private Ltd Imatinib Mesylate API Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio
  108. 8.18.5 Acebright India Pharma Private Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Imatinib Mesylate API Value Chain Analysis
  2. 9.1.1 Imatinib Mesylate API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Imatinib Mesylate API Production Mode & Process
  6. 9.2 Imatinib Mesylate API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Imatinib Mesylate API Distributors
  9. 9.2.3 Imatinib Mesylate API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst